Search

Your search keyword '"Fabrizio Tabbò"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Fabrizio Tabbò" Remove constraint Author: "Fabrizio Tabbò"
108 results on '"Fabrizio Tabbò"'

Search Results

1. REHABILITATION NEEDS AND PERSPECTIVES IN LONG-TERM LUNG CANCER SURVIVORS

2. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

5. HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway

6. Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

7. Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

8. Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

9. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

10. SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

11. Genetics of Follicular Lymphoma Transformation

12. The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank.

13. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study

14. Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

15. Expert consensus on perioperative treatment for non-small cell lung cancer

16. Supplemental Figure 3 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

17. Supplemental Figure 1 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

18. Supplemental Figure 2 from Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells

19. Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

20. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

21. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

22. Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

23. Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management

24. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences

25. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)

26. RNA SEQUENCING REVEALS DIFFERENT GENE EXPRESSION IN MALE VERSUS FEMALE DIFFUSE LARGE B‐CELL LYMPHOMA

27. Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations

28. The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences

29. MA12.07 Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center

30. P59.20 Natural History of KRAS Mutant Non-Small-Cell Lung Cancer in the Immunotherapy Era: A Single-Centre Retrospective Study

31. 1368TiP EPROPA: The European program for routine testing of patients with advanced lung cancer

32. 1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients

33. Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas

34. Contributors

35. Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

36. The ALK receptor tyrosine kinase journey: From physiological roles to pathological disruptions

37. Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center

38. Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective

39. Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

41. ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients

42. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways

43. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

44. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >= 50%: a multicenter study with external validation

45. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5

46. SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

47. Future perspectives from lung cancer pre-clinical models: new treatments are coming?

48. Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

49. Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma

50. Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread?

Catalog

Books, media, physical & digital resources